Tyme’s Post

SK to sell down stakes in VIC (Vingroup) SK Investment Vina II plans to sell over 50.8 million VIC shares between January 16 and February 14, 2025, reducing its stake in Vingroup from 6.05% to 4.72%, effectively ending its major shareholder status. This divestment is part of SK Group's ongoing restructuring of its investment portfolio, including its holdings in Vietnam. HSC Research maintain our Hold rating and RNAV derived VND42,600 TP. VIC now trades at a 15.0% discount to RNAV, narrow vs. its 3-yr avg. of 28.8%. HSC Research --- Please comment or inbox me to receive full report #VietNamStockMarket #HSC #VIC #Vingroup #SKGroup

#Apax's Zellis Eyes Benify Acquisition in European Tech Surge In a significant move for the European technology sector, Zellis, backed by Apax Partners, is nearing a deal to acquire the employee benefits platform Benify. This acquisition is part of an accelerating trend in tech deal-making across Europe. The deal, reportedly valued at several hundred million dollars, is expected to be announced soon. Vitruvian Partners, Benify's current owner, acquired the platform back in 2011, and the company now serves over 3 million users. With Apax's recent acquisition of Zellis from Bain Capital for £1.25 billion, this new potential acquisition further positions Zellis as a key player in the industry. As the European tech sector heats up, what could this mean for future market dynamics? #Zellis #ApaxPartners #Benify #TechAcquisition #EuropeanTech #MarketTrends #EmployeeBenefits #SaaSverse

It’s Official! 🎉   CoreRx, Inc. is thrilled to announce the successful completion of its acquisition of Societal™ CDMO . This strategic merger marks a significant milestone for both companies as they unite to offer even greater value and innovation to their clients and the patients they serve.   CoreRx and Societal are committed to ensuring a seamless transition and uninterrupted service for existing clients while also exploring new opportunities for collaboration and growth. As CoreRx and Societal™ CDMO embark on this journey together, clients can expect continued dedication to quality, reliability, and customer satisfaction. A link to the full press release can be found here: https://lnkd.in/g4AR5pcg. #DrugDevelopment #CDMO #PharmaInnovation #IndustryLeadersUnite #InnovativePartnerships #CollaborativeExcellence #StrategicAcquisition #GrowthThroughAcquisition #QHPCapital

ActiveX Corporation has entered into a joint venture with Katawat El-Tabadel, represented by its Chairman, Mr. Adnan Abdullah Al Nuaim. Through this partnership, both existing and new customers in the Middle East will now have access to ActiveX's services via the newly established joint venture company.

CEO Mo Khan discusses hVIVO’s €10M acquisition and growth plan - ICYMI @hVIVO_UK #AIM #HVO. hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan talked with Proactive about a strong start to 2025, including record revenue for 2024 and a €10 million acquisition of two clinical research units in Germany from CRS. Khan highlighted achieving £63 million in revenue for 2024, a 12% increase over 2023, with industry-leading EBITDA margins of 26% and a cash position of £44 million. The acquisition of CRS’s Mannheim and Kiel units adds 120 beds and expands hVIVO’s clinical trial offerings, diversifying services and customer reach. Khan emphasized the strategic importance... http://ow.ly/uymB105YrEW

We are excited to announce that BIP Ventures has led the Series A funding round for KORIO, an innovative leader in Randomization & Trial Supply Management (RTSM) technology. This partnership reflects our commitment to supporting solutions that address critical challenges in clinical trials. Austin Poole, General Partner at BIP Ventures, said, “In an industry where legacy solutions often struggle with the growing complexity of study designs, Korio’s RTSM platform successfully solves issues like delays, quality concerns, and excessive costs.” Learn more about this partnership and how Korio is reshaping the RTSM landscape. 🔗 https://buff.ly/3Xl08wI #RTSM #ClinicalTrials #Innovation #HealthTech #VentureCapital #PrivateMarkets #BIPVentures #HealthcareTransformation

Stout is pleased to announce that its client, OpenClinica, a portfolio company of Thompson Street Capital Partners (TSCP), has acquired BuildClinical. Learn more: https://hubs.ly/Q02_7lzy0

Opyl announces a transformative joint venture with X Firm, set to revolutionize clinical trial outcomes and increase market reach across EMEA and North America. Read More https://lnkd.in/giSHdbKm #JointVenture, #TrialKey, #fundingRaise, #clinicalTrials, #marketExpansion

In yet another acquisition in our sector, Exosens announced last week that it has entered into exclusive negotiations to acquire Noxant. Read the details: https://bit.ly/499bNo4